Fundraising FoxvenBio Global Strategic
Venture capitalSan Francisco · 7 people tracked
Find your way into venBio Global Strategic
2,356 people in our graph share verified history with the venBio Global Strategic team — schools, employers, funds. One of them is your warm intro.
Fund manager profile
venBio Global Strategic is a venture fund manager based in San Francisco. SEC filings show 4 venture funds on record, most recently venBio Global Strategic Fund V, L.P. filed July 2024.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
What founders say
No founder feedback on venBio Global Strategic yet.
Team · 7 people
from public directories
What they invest in
from 18 of 20 portfolio companiesBiotech ×17Healthtech ×10Medical Devices ×7Deep Tech ×3AI & Machine Learning ×2Digital Health ×2Longevity ×1
HQs:United States×19Australia×1
Investments · 20 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 32024 · 42023 · 22022 · 22021 · 619 dated
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Board seatRichard Gaster· per SEC Form D · $259M raise · filed Mar 2024
Co-investorsForesite CapitalHBM Healthcare InvestmentsHBM PartnersNextech InvestOrbiMedSamsara BioCapital+3 more
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey Aronin(Director)inJeffrey M. Dayno, M.D.(President and Chief Executive Officer)inPatrick Morris(Secretary and Treasurer)inRobert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)
BoardAaron Royston(Director)in
Co-investorsAisling CapitalHBM Healthcare InvestmentsHBM PartnersParagon Biosciences LLCPivotal Life SciencesValor Equity Partners+3 more
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)inJohn Kincaid(Chief Scientific Officer)inDavis Ryman(Executive Officer)inMicah Zajic(Executive Officer)inIan Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Board seatRichard Gaster· per SEC Form D · $50.4M raise · filed May 2024
Co-investorsCoastCapCTI Life Sciences Fund L.P.FJ LabsLuma GroupSofinnova VenturesvenBio Partners+1 more
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)inLaura Norris(Executive Officer, Director)inTimothy Read(Executive Officer, Director)Eric Martin(Executive Officer)in
BoardAmit Mehta(Director)
Board seatAaron Royston· per SEC Form D · $35.3M raise · filed Nov 2025
Co-investorsFifty YearsFundersClubTau VenturesvenBio PartnersY CombinatorAlamo Angels+8 more
Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.
BiotechHealthtechMedical DevicesSan Diego, US
Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)Fred Aslan(Executive Officer, Director)inJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)Peter Flynn(Executive Officer)in
Board seatYvonne Yamanaka· per SEC Form D · $120M raise · filed Apr 2021
Co-investors5AM VenturesEcoR1 CapitalRA CapitalvenBio Partners
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)inGreg Bell(Executive Officer)
Board seatCorey GoodmanRichard Gaster· per SEC Form D · $56M raise · filed Feb 2024
Co-investorsAlpha Wave GlobalBioBritLifeSci Venture PartnersvenBio PartnersJanus Henderson InvestorsREDMILE+2 more
Entact is a drug discovery company developing treatments for patients.
BiotechDeep TechWatertown, US
Victoria Richon(Executive Officer, Director, Promoter)inRuben Tommasi(Chief Scientific Officer)Michael Gutch(Chief Operating Officer)Alon Lazarus(Director)
BoardAndrew Sinclair(Director)Anna French(Director)in
Board seatRichard Gaster· per SEC Form D · $10M raise · filed Jun 2026
Co-investorsvenBio PartnersAbingworth
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform.
BiotechDigital HealthMedical DevicesRedwood City, US
Emmett Cunningham(Executive Officer, Director)inMark Bachleda(Executive Officer, Director)inRobert Vitti(Executive Officer)inOliver Stauch(Executive Officer)inConrad Wang(Director)in
Board seatYvonne Yamanaka· per SEC Form D · $89.8M raise · filed Oct 2025
Co-investorsFrazier Life SciencesHealthQuest CapitalvenBio PartnersRA Capital
FogPharma develops ultra-tunable Helicon peptide therapeutics designed to reach historically undruggable targets, aiming to treat cancer and other serious diseases.
BiotechBoston, US
Gregory L Verdine(Executive Officer, Director)Mathai Mammen(CEO, President and Chairman)in
Board seatCorey S. Goodman· per SEC Form D · $178M raise · filed Dec 2022
Co-investorsCatalio Capital Management, LPHorizons VenturesGV (Google Ventures)
Impel Pharmaceuticals develops therapies for diseases with high unmet medical needs by pairing established drugs with its proprietary upper-nasal drug delivery technology.
BiotechHealthtechMedical DevicesSeattle, US
John D. Hoekman(Executive Officer, Director)in
BoardMichael Hite(Director)Stewart Parker(Director)
Board seatAaron Royston· per SEC Form D · $1.9M raise · filed Apr 2021
Co-investors5AM VenturesB Capital GroupvenBio PartnersWestlake Village BioPartners
.jpeg){kind=logo}
Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data.
AI & Machine LearningBiotechDeep TechChippendale, AU
Tim Craven(CEO)inToby Passioura(CSO)inGlen McIntyre(COO)
BoardMATT HERSHENSON(Director)in
Board seatCorey Goodman· per SEC Form D · $2.3M raise · filed Dec 2023
Co-investorsBEVCCivilization Ventures Management, LlcMRL Ventures FundPlayground GlobalvenBio PartnersAxial VC
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
BoardDAVID ALLISON(Director)in
Board seatAaron Royston· per SEC Form D · filed Jul 2021
Co-investors5AM VenturesOrbiMedSamsara BioCapitalvenBio PartnersVivo CapitalRTW Investments L.P.+1 more
NFlection is a biopharmaceutical company developing novel therapeutics.
BiotechMedical DevicesBoston, US
Christopher Powala(Chief Development Officer, Former President & CEO)Mark de Souza(Executive Officer, Director)in
BoardKetan Patel(Director)in
Board seatCorey Goodman· per SEC Form D · $4M raise · filed Jul 2023
Co-investorsF-Prime CapitalvenBio Partners
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
Board seatAaron Royston· per SEC Form D · $167.9M raise · filed Sep 2022
Co-investorsLifeSci Venture PartnersSamsara BioCapitalScion Life SciencesSofinnova VenturesTCG CrossovervenBio Partners+2 more
HealthtechIrvine, US
Kenny Chang(Executive Officer)W. Ronald Redmond(Director)Vijay Dhaka(Executive Officer)Philong Pham(Executive Officer, Director)Hongsheng Tong(Executive Officer, Director)
Board seatAaron Royston· per SEC Form D · $112M raise · filed Sep 2021
Co-investorsBlackRockEndeavour VisionMVM Life Science PartnersRTW Investments L.P.Soleus CapitalVivo Capital
Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications.
BiotechHealthtechMedical DevicesBurlingame, US
Hong Wan(Executive Officer, Director)in
BoardRan Geng(Director)Michael Carusi(Director)Isaac Cheng(Director)Christine Brennan(Director)
Board seatCorey Goodman· per SEC Form D · $61.6M raise · filed Jul 2021
Co-investorsLightstone VenturesMRL Ventures FundvenBio PartnersMatrix Partners China
San Diego, US
Mark S. Forman(Executive Officer)inMatthew Moore(Executive Officer)inJohn Nuss(Executive Officer)inJigar Choksey(Director)Martin Auster(Executive Officer)inChristopher W. Krueger(Executive Officer)
Board seatAaron RoystonRichard Gaster· per SEC Form D · $51M raise · filed Sep 2021
Co-investorsNew Science VenturesThird Point VenturesvenBio PartnersSilverArc Private
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in
BoardCorey . Goodman(Director)inJonathan Leff(Director)in
Co-investorsvenBio PartnersMRL Ventures FundSofinnova VenturesCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture Partners+8 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Caldera Therapeutics, Inc.ImmPACT Bio USA Inc.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
2 IPOsAlumisNASDAQ: ALMSHarmony BiosciencesNASDAQ: HRMY
Portfolio news
latest coverage across their companiesAeovian Pharmaceuticals · finsmes.com · Dec 16, 2025
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Harmony Biosciences | 6.3% | $24.00 | Aug 2020 | $96.6M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has venBio Global Strategic made?
- venBio Global Strategic has 20 tracked investments, 2 of which have exited, including 6 dated in the last 24 months.
- Where is venBio Global Strategic located?
- venBio Global Strategic is headquartered in San Francisco, US.